Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Clinical trial NCT03184571 · COMPLETED

Trial details

NCT number: NCT03184571
Sponsor: BerGenBio ASA
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Metastatic NSCLC Stage IV Adenocarcinoma of Lung

Start date: 2017-10-02
Primary completion: 2022-10-27
Enrollment: 99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.